CME: Diabetic Macular Edema Treatment in the 21st Century

Diabetic Macular Edema Treatment in the 21st Century

Diabetic Macular Edema Treatment in the 21st Century
Dr. Sun explains the DRCR Network's treatment algorithm for diabetic macular edema and reviews its safety and efficacy.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity will discuss the DRCR Network’s treatment algorithm for diabetic macular edema (DME) as well as the treatment results obtained by using this algorithm. Also covered will be how to avoid under-treatment in the first year of therapy and over-treatment thereafter, the average number of injections that will be administered over a period of 5 years, safety of deferring injections after 6 months for eyes with persistent, stable DME, and the interaction between initial visual acuity and differences in outcomes among 3 anti-vascular endothelium growth factor, or anti-VEGF agents.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Jennifer K. Sun, MD, MPH
    Associate Professor of Ophthalmology
    Chief, Center for Clinical Eye Research and Trials
    Joslin Diabetes Center
    Harvard Medical School
    Boston, MA

    Dr. Sun has nothing to disclose.


    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Neil M. Bressler, MD is Principal Investigator for Acucela, Allergan Inc, Apeliotus Technologies, AstraZeneca, Athenagen, Bausch & Lomb, Carl Zeiss Meditec, Fovea, Genentech, Inc, Jerini, Notal Vision, Inc, Novartis, OSI (Eyetech), Othera, QLT, Regeneron, and TargeGen. His spouse serves as a consultant for AstraZeneca, Genentech, Inc, Notal Vision, Inc, Oxigene, Potentia Pharmaceuticals, and Pfizer Inc.
    • Robert Schneider, MSW has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the treatment algorithm for DME
    • Recognize the treatment results obtained by using this algorithm
  • Target Audience

    This activity is designed to meet the educational needs of Retinal Specialists, General Ophthalmologists, Ophthalmology Nurse Practitioners, Ophthalmology Physician Assistants, and Optometrists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and the Diabetic Retinopathy Clinical Research Network, sponsored by the National Eye Institute of the National Institutes of Health. TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 


  • Commercial Support

    There is no commercial support for this activity. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Prova Education newsletters.

Better education for a better you.

* Required

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free